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Experimental Study
Glimepiride Treatment Facilitates
Ischemic Preconditioning
in the Diabetic Heart
Derek J. Hausenloy, FRCP, PhD1, Abigail M. Wynne, MPhil1,
Mihaela M. Mocanu, PhD1, and Derek M. Yellon, DSc1
Abstract
Aims: The diabetic heart is resistant to the myocardial infarct-limiting effects of ischemic preconditioning (IPC). This may be in
part due to the downregulation of the phosphatidylinositol 30-kinase-Akt pathway, an essential component of IPC protection. We
hypothesized that treating the diabetic heart with the sulfonylurea, glimepiride, which has been reported to activate Akt, may
lower the threshold required to protect the diabetic heart by IPC.Methods:Goto-Kakizaki rats (a type II lean model of diabetes)
received glimepiride (20 mg/kg per d, by oral gavage) or vehicle for (a) 3 months (chronic treatment) or (b) 24 hours (subacute
treatment). In the third group, glimepiride (10 mmol/L) was administered only to the isolated hearts on the Langendorff apparatus
(acute treatment). All hearts were subjected to 35 minutes ischemia and 120 minutes reperfusion ex vivo, at the end of which
infarct size was determined by tetrazolium staining. Preconditioning treatment comprised 1 (IPC-1) or 3 (IPC-3) cycles of 5
minutes global ischemia and 10 minutes reperfusion. Results: The diabetic heart was found to be resistant to IPC such that
3-IPC cycles, instead of the usual 1-IPC cycle, were required for cardioprotection. However, pretreatment with glimepiride
lowered the threshold for IPC such that both 1 and 3 cycles of IPC elicited cardioprotection: chronic glimepiride treatment
(IPC-1 31.9%+ 3.8% and IPC-3 33.5%+ 2.4% vs 43.9%+ 1.4% control, P < .05; N > 6 per group); subacute glimepiride treat-
ment (IPC-1 31.1%+ 3.0% and IPC-3 29.3%+ 3.3% vs 42.2%+ 2.3% control, P < .05 N > 6 per group); and acute glimepiride
treatment (IPC-1 28.2% + 3.7% and IPC-3 24.6% + 5.4% vs 41.9% + 5.4% control, P < .05; N > 6 per group). This effect of
glimepiride was independent of changes in blood glucose. Conclusions:We report for the first time that glimepiride treatment
facilitates the cardioprotective effect elicited by IPC in the diabetic heart.
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Introduction
Coronary heart disease (CHD) is a leading cause of death in dia-
betic patients. The number of diabetic patients is increasing at an
alarming rate and is estimated to reach 300 million worldwide
according to the World Health Organization. Diabetic patients
are 2 to 3 times more likely to develop CHD, and experience
worse clinical outcomes following an acute myocardial infarc-
tion,1-3 coronary angioplasty,4 and cardiac bypass surgery.5-7
The reason for the worsened cardiovascular outcomes in diabetic
patients is currently unclear. Preclinical animal studies suggest
that there may be specific defects in diabetic cardiomyocytes
which may be responsible including increased mitochondrial
generation of reactive oxygen species, downregulation of the
PI3-Akt survival kinase pathway, and reduced rates of adenosine
triphosphate (ATP) synthesis (reviewed in refs 8-10).
One potential endogenous strategy for protecting the
diabetic heart against acute ischemia-reperfusion (I/R) injury
is ischemic preconditioning (IPC), a phenomenon which was
first described in 1986 by Murry and colleagues,11 as the
reduction in myocardial infarct size observed in canine hearts
pretreated with short bouts of nonlethal myocardial ischemia
and reperfusion. Whether the diabetic myocardium is amenable
to the cardioprotective effects of IPC has been debated with
reports of cardioprotection in some experimental studies.12-16
However, the vast majority of studies find that the diabetic
heart is resistant to the cardioprotection elicited by IPC.17-33
The fact that the diabetic heart may be resistant to IPC may
impact on the translation of novel cardioprotective strategies
into the clinical setting where about 15% to 20% of the patients
with CHD are also diabetic.34-36 Studies from our laboratory
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have also found that the diabetic heart is resistant to IPC, but this
resistance can be overcomewhen a stronger IPC stimulus is used
to elicit cardioprotection.16,37 Initial findings have suggested
that this abnormal response of the diabetic heart to IPC may
be due to impaired phosphatidylinositol 30-kinase (PI3K)-Akt
signaling.16 Previous studies have clearly established a role
for the PI3K-Akt pathway in the signal transduction pathway
underlying IPC-induced cardioprotection in the nondiabetic
heart.38,39
Importantly, the antidiabetic sulfonylurea, glibenclamide,
which is used less frequently nowadays, is known to block
the cardioprotective effects of IPC by acting as an antagonist
of the mitochondrial ATP-dependent potassium channel.40,41
Interestingly, the sulfonylurea, glimepiride, which does not
block IPC cardioprotection,42 has been reported to activate Akt
when administered to the endothelial cells,43 human umbilical
vein endothelial cells,44 and adipocytes.45 In the present study,
we investigate whether pretreatment with glimepiride can
facilitate IPC in the diabetic heart.
Materials and Methods
Animals and Materials
Adult Goto-Kakizaki rats, a rat model of type II diabetes
mellitus, were purchased from Denmark (Taconic, Den-
mark).46,47 Animals received humane care in accordance with
the United Kingdom Animal (Scientific Procedures) Act of
1986. For oral gavage, glimepiride (20 mg/kg/d) was dissolved
in methylcellulose. For the Langendorff perfusion, glimepiride
(10 mmol/L, Sigma, UK) dissolved in dimethyl sulfoxide
(DMSO) was further dissolved in Krebs-Henseleit buffer, giv-
ing a final DMSO concentration of <0.01%. All other reagents
were of standard analytical grade.
Glimepiride Pretreatment Protocols
Animals were randomized to receive 1 of the following 3
glimepiride treatment protocols:
Chronic glimepiride treatment. Rats received either glimepiride
(20 mg/kg per d) dissolved in methylcellulose or methylcellu-
lose vehicle control by oral gavage for 3 months, following
which the hearts were excised and mounted on the Langendorff
apparatus and subjected to the treatment protocols outlined in
Figure 1.
Subacute glimepiride treatment. Rats received either glime-
piride (20 mg/kg per d) dissolved in methylcellulose or
methylcellulose vehicle control by oral gavage for 24 hours,
following which the hearts were excised and mounted on
the Langendorrf-apparatus and subjected to the treatment
protocols outlined in Figure 1.
Acute glimepiride treatment. Hearts were excised from
untreated animals and mounted on the Langendorff apparatus,
and were perfused for 15 minutes with either glimepiride
(10 mmol/L) or vehicle control (DMSO, <0.01%) prior to the
treatment protocols outlined in Figure 1.
Figure 1. Experiment protocols. Hearts were randomized to receive 1 of the 3 different glimepiride treatment regimens depicted in the
scheme. Following pretreatment with glimepiride, all hearts were randomized to receive either control, 1 cycle of IPC (IPC-1) or 3 cycles of
IPC (IPC-1), with each cycle of IPC comprising 5 minutes of global myocardial ischemia followed by 10 minutes of myocardial reperfusion. IPC
indicates ischemic preconditioning.
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Myocardial Infarction Protocols
All hearts were subjected to 35 minutes of regional ischemia
followed by 120 minutes of reperfusion at the end of which
infarct size was determined by tetrazolium staining. Hearts were
randomized to the following treatment groups (see Figure 1):
1. Control.Hearts were subjected to the standard I/R protocol
as above.
2. IPC-1. Hearts were preconditioned with one 5-minute
episode of global myocardial ischemia followed by 10
minutes of reperfusion prior to the index ischemic period.
3. IPC-3. Hearts were preconditioned with three 5-minute
episodes of global myocardial ischemia with 10 minutes
of intervening reperfusion prior to the index ischemic
period.
Langendorff Perfusion of Rat Hearts
Rats were anesthetized with sodium pentobarbital (55 mg/kg
intraperitoneally) and heparin (300 IU). The hearts were
rapidly excised into ice-cold buffer and mounted on a constant
pressure (80 mm Hg) Langendorff perfusion apparatus and
perfused with modified Krebs-Henseleit bicarbonate buffer in
mmol/L: NaCl 118.5, NaHCO3 25.0, KCl 4.8, MgSO4 1.2,
KH2PO4 1.2, CaCl2 1.7, and glucose 11.0. The buffer was
gassed with 95%O2/5%CO2 and pH maintained at 7.35 to
7.45 at 37.0C. A suture was placed around the left main cor-
onary artery and the ends were inserted into a pipette tip to
form a snare. A latex, fluid-filled balloon was placed in the left
ventricle through an incision in the left atrial appendage and
inflated to a pressure of 8 to 10 mm Hg. Left ventricular devel-
oped pressure, heart rate, and coronary flow were monitored at
regular intervals. Temperature was constantly measured via a
thermoprobe inserted into the pulmonary artery and maintained
at 37.0C + 0.2C.
Regional myocardial ischemia was induced by tightening the
suture placed around the left main coronary artery and reperfu-
sion initiated by releasing the snare. At the end of the reperfusion
period, the suture was tied and the heart was perfused with
0.25% Evans Blue in saline to delineate the area at risk. Hearts
were then frozen at 20C for several hours before being sliced
into 2-mm thick transverse sections and incubated in triphenyl-
tetrazolium chloride solution (TTC; 1% in phosphate buffer).
The TTC reacts with intracellular dehydrogenases to stain viable
risk zone tissue red leaving the infarcted areas off-white. The
slices were then transferred and fixed in 10% formalin overnight.
The slices were drawn onto acetate and computerized planimetry
(Summa Sketch III, Summagraphics, Seymour, Connecticut)
was used to assess the percentage of infarcted tissue in the
myocardium risk zone area (I/R%).48
Blood Glucose and Glycated Hemoglobin Assessment
Samples for nonfasting blood glucose and glycated hemoglobin
(HbA1c) were taken at baseline and after 3 months treatment
with either glimepiride or methylcellulose control. Blood glu-
cose measurements (mmol/L) were determined using an ABL
700 series blood gas analyzer (Radiometer, Copenhagen) and
HbA1c measurements (%) were determined by an antibody-
colorimetric assay using a Cobas Mira Plus analyzer (Roche
Diagnostic Systems, Roche, UK).
Statistical Analysis
All values are expressed as mean+ standard error of the mean.
Myocardial infarct size was analyzed by 1-way analysis of
variance and Fisher protected least significant difference test
for multiple comparisons. Differences were considered
significant when P < .05.
Results
The Threshold for IPC Is Elevated in Untreated Diabetic
Hearts
Diabetic untreated hearts were resistant to the cardioprotection
elicited by 1 cycle of IPC and required 3 cycles of IPC before a
reduction in myocardial infarct size was observed, whether the
heart had been subjected to pretreatment with chronic vehicle
control (IPC-3 27.1% + 3.5% vs control 38.4% + 5.1%,
P < .05; IPC-1 33.1% + 4.7% vs control 38.4% + 5.1%,
P ¼ not significant [NS]), subacute vehicle control (IPC-3
26.0% + 5.9% vs control 42.3% + 2.8%, P < .05; IPC-1
43.0% + 4.7% vs control 42.3% + 2.8%, P ¼ NS) or acute
vehicle control (IPC-3 28.6% + 6.0% vs control
42.6% + 5.3%, P < .05; IPC-1 36.8% + 4.5% vs control
42.6%+ 5.3%, P ¼ NS; see Figures 2 to 4).
Figure 2. Myocardial infarct size (expressed as a percentage of the
volume of myocardium at risk) in hearts excised from rats pretreated
with 3 months of either glimepiride (20 mg/kg/d) or methylcellulose
vehicle by oral gavage. The results demonstrate that diabetic hearts
are resistant to IPC such that 3 cycles (IPC-3) instead of the usual 1
cycle (IPC-1) of IPC are required to reduce myocardial infarct size.
However, glimepiride pretreatment facilitates IPC such that both 1
and 3 cycles of IPC elicit cardioprotection. Values are mean + SEM.
*P < .05. N > 6 per group. IPC indicates ischemic preconditioning;
SEM, standard error of the mean.
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Glimepiride Pretreatment Facilitates IPC in the
Diabetic Heart
Interestingly, pretreatment with glimepiride facilitated IPC such
that both 1 and 3 cycles of the IPC were able to elicit
cardioprotection, irrespective of whether the heart had been
subjected to pretreatment with chronic glimepiride (IPC-1
31.9% + 3.8% and IPC-3 33.5% + 2.4% vs 43.9% + 1.4%
control,P< .05), subacute glimepiride (IPC-131.1%+ 3.0% and
IPC-329.3%+3.3% vs42.2%+ 2.3% control,P< .05), or acute
glimepiride (IPC-1 28.2%+ 3.7% and IPC-3 24.6%+ 5.4% vs
41.9%+ 5.4% control, P < .05; see Figures 2 to 4).
Blood Glucose and HbA1c
Three months treatment of glimepiride or methylcellulose did
not affect nonfasting blood glucose (in mmol/L: 7.1 + 0.8 in
glimepiride-treated animals at baseline vs 5.9 + 0.9
glimepiride-treated animals after 3 months; 7.0 + 1.0 in
methylcellulose-treated animals at baseline vs 6.1 + 0.7
methylcellulose-treated animals after 3 months; P > .05). Nor
was there any change in HbA1c (from 4.0 + 0.2 at baseline
to 4.1%+ 0.2% in glimepiride-treated animals after 3 months
vs 4.1+ 0.2 in methylcellulose-treated animals after 3 months;
P > .05). The HbA1c values were considered diabetic when
>3.45% using our assay.
Discussion
The main findings from the present study are as follows: (a) we
confirm that the diabetic heart is resistant to IPC such that 3
cycles of IPC instead of the usual 1 cycle are required to elicit
cardioprotection; (b) the resistance to IPC observed in the
diabetic heart can be overcome by pretreatment with the
sulfonylurea, glimepiride, such that both 1 and 3 cycles of IPC
confer cardioprotection in the diabetic heart; (c) this effect of
glimepiride in facilitating IPC appears to be independent of its
glucose-lowering effects, as evidenced by the lack of change in
fasting glucose levels of HbA1c over 3 months glimepiride
therapy.
The majority of previous experimental studies have demon-
strated the diabetic heart to be resistant to the cardioprotection
elicited by IPC,17-33 attributing the inability to precondition the
diabetic myocardium to hyperglycemia,19 impaired mitochon-
drial function,32 and sarcolemmal KATP function.
23,28 In the
current study, we too find that the diabetic heart is resistant
to IPC, but that this can be overcome by increasing the IPC sti-
mulus or treating with glimepiride. Our previous study15
demonstrated that the diabetic heart was resistant to IPC,
although this could be overcome by applying 3 cycles of the
standard 1 IPC cycle. In the nondiabetic Wistar control rat, a
single cycle of IPC was sufficient to achieve cardioprotection.
In that study, the resistance to IPC was attributed to impaired
signaling through the PI3K-Akt pathway, a key mediator of
IPC-induced cardioprotection.16 It has been well-established
that PI3K-Akt signaling is impaired in diabetic animals,8 and
that PI3K-Akt signaling in both the preischemic and the
postischemic reperfusion phases underlies the cardioprotection
elicited by IPC in nondiabetic animal hearts.38,39,49 However,
in some large animal studies the contribution of PI3K-Akt
signaling to reperfusion protection has been questioned with
Figure 3. Myocardial infarct size (expressed as a percentage of the
volume of myocardium at risk) in hearts excised from rats pretreated
with 24 hours of either glimepiride (20 mg/kg/d) or methylcellulose
vehicle by oral gavage. The results demonstrate that diabetic hearts
are resistant to IPC such that 2 cycles (IPC-3) instead of the usual 1
cycle (IPC-1) of IPC are required to reduce myocardial infarct size.
However, glimepiride pretreatment facilitates IPC such that both 1
and 3 cycles of IPC elicit cardioprotection. Values are mean + SEM.
P < .05. N > 6 per group. IPC indicates ischemic preconditioning; SEM,
standard error of the mean.
Figure 4. Myocardial infarct size (expressed as a percentage of the
volume of myocardium at risk) in rat hearts pretreated with either
glimepiride (10 mmol/L) or vehicle control (<0.01% DMSO) on the
Langendorff apparatus. The results demonstrate that diabetic hearts
are resistant to IPC such that 2 cycles (IPC-3) instead of the usual 1
cycle (IPC-1) of IPC are required to reduce myocardial infarct size.
However, glimepiride pretreatment facilitates IPC such that both 1
and 3 cycles of IPC elicit cardioprotection. Values are mean + SEM.
P < .05. N > 6 per group. DMSO indicates dimethyl sulfoxide; IPC,
ischemic preconditioning; SEM, standard error of the mean.
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the suggestion that the Survival Activator Factor Enhancement
pathway being more important in this setting.50-53 It would be
interesting to determine whether glimepiride facilitates IPC by
activating the PI3K-Akt pathway in the diabetic heart. In this
regard, glimepiride has been reported to activate Akt in both
coronary endothelial cells,43 human umbilical vein endothelial
cells,44 and adipocytes.45 Furthermore, it has been reported that
the peroxisome proliferator-activated receptor (PPAR)-g
agonist, rosiglitazone, also has the ability to cardioprotect the
diabetic rat heart through the activation of Akt.54 Whether rosi-
glitazone would also overcome the resistance for IPC in the
diabetic heart remains to be determined. One limitation of the
present study is that we did not investigate whether the effect of
glimepiride pretreatment on the threshold for IPC was
mediated through the activation of the PI3K-Akt pathway.
Whether antidiabetic therapy with glimepiride has the same
effect on the cardioprotective efficacy of IPC in the diabetic
patient is unknown given that the findings in our experimental
study were undertaken in the ex vivo perfused rat heart.
With respect to IPC, previous studies by our laboratory and
others have reported that the sulfonylurea glibenclamide but
not glimepiride42,55,56 or gliclazide57 has the ability to abolish
the cardioprotective effect elicited by IPC from its antagonistic
actions on the ATP-dependent potassium channels within
cardiac mitochondria, which are recognized to be pivotal to
IPC-induced cardioprotection.58 In the current study, we
demonstrate that the antidiabetic sulfonylurea, glimepiride, is
able to modify the response of the diabetic heart to IPC, but
does not elicit cardioprotection itself suggesting that glimepir-
ide is somehow potentiating the IPC signal. The mechanism
through which glimepiride actually lowers the threshold for
IPC in the diabetic heart is unclear, especially considering the
different regimens in which it was shown to be effective. We
speculate that glimepiride potentiates the PI3K-Akt signaling
pathway in the diabetic heart which upregulates downstream
signaling mechanistic pathways important in preconditioning.
Whether the effect of glimepiride in overcoming the resistance
of IPC in the diabetic heart is specific to this antidiabetic
medication is unknown. Interestingly, the other classes of
antidiabetic mediation such as PPAR-g agonists59 and metfor-
min60 have been demonstrated to confer cardioprotection in
their own right.
In conclusion, we demonstrate that the treatment with the
sulfonylurea glimepiride facilitates IPC such that the resistance
to IPC observed in the diabetic heart is overcome. Therefore,
certain types of antidiabetic medication may facilitate IPC and
permit diabetic patients with CHD to benefit from this
endogenous form of cardioprotection.
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